NDC 71390-125
Barhemsys
Amisulpride
Barhemsys is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Acacia Pharma Ltd. The primary component is Amisulpride.
| Product ID | 71390-125_3aa09356-e93c-40c1-bb84-547ac93f1388 |
| NDC | 71390-125 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Barhemsys |
| Generic Name | Amisulpride |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2020-02-27 |
| Marketing Category | NDA / NDA |
| Application Number | NDA209510 |
| Labeler Name | Acacia Pharma Ltd |
| Substance Name | AMISULPRIDE |
| Active Ingredient Strength | 3 mg/mL |
| Pharm Classes | Dopamine D2 Antagonists [MoA], Dopamine-2 Receptor Antagonist [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 71390-125-20
10 CARTON in 1 PACKAGE (71390-125-20) > 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-21) > 2 mL in 1 VIAL, SINGLE-DOSE
| Marketing Start Date | 2020-02-27 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [Barhemsys]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 BARHEMSYS 87808035 5620798 Live/Registered |
Acacia Pharma Limited 2018-02-22 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.